Why the Zelda Therapeutics Ltd share price rocketed 20% higher today

The Zelda Therapeutics Ltd (ASX: ZLD) share price has been one of the biggest movers on the market today.

At the time of writing the medicinal cannabis company’s shares are up 20% to 8.9 cents.

What happened?

This morning Zelda announced that it has entered into a strategic manufacturing and distribution agreement with Chile-based Knop Laboratorios.

According to the release management believes the agreement will form an important part of Zelda’s Chilean activities.

As well as locking in a high quality supply of Zelda’s formulated medicinal-cannabis medicines for its planned clinical trials, the agreement secures a scalable and GMP-grade source of commercial quantities following product registration.

Furthermore, as Knop operates a chain of pharmacies throughout Chile, it could potentially become a key distribution channel for Zelda’s products following the completion of its clinical trials.

Zelda’s trials are focused on insomnia, eczema and autism. Results for its insomnia and eczema trials are expected to be released by the end of the year. If all goes to plan the company could be generating sales in the not so distant future.

Should you invest?

Like its peers Creso Pharma Ltd (ASX: CPH) and Auscann Group Holdings Ltd (ASX: AC8), I think Zelda has significant growth potential.

However, there is still a long road ahead and many challenges to overcome. For this reason I will continue to watch on from the sidelines with a keen interest.

In the meantime I will be considering an investment in one of these explosive growth shares.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.